15 March 2022 - Europe's drug regulator said on Tuesday it had begun reviewing AstraZeneca's application for antibody based COVID-19 therapy, a key step towards approval of the treatment in the region, but gave no timeline for a conclusion.

The decision by the human medicines committee of the European Medicines Agency comes after it began reviewing data on the drug in October.

Read Reuters article